Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for autoimmune disorders.

C H Evans1, S C Ghivizzani, T J Oligino

  • 1Center for Molecular Orthopaedics, Department of Orthopaedic Surgery, Harvard Medical School, Boston, Massachusetts 02115, USA. cevans@rics.bwh.harvard.edu

Journal of Clinical Immunology
|October 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Home delivery for chondrocytes.

Osteoarthritis and cartilage·2025
Same author

How to Cure Rhus Poisoning.

The Homoeopathic physician·2023
Same author

Enthesis: not the same in each localisation - a molecular, histological and biomechanical study.

European cells & materials·2022
Same author

Mechanical and strain behaviour of human Achilles tendon during in vitro testing to failure.

European cells & materials·2022
Same author

Reverse dynamisation: a modern perspective on Stephan Perren's strain theory.

European cells & materials·2021
Same author

Healing of sub-critical femoral osteotomies in mice is unaffected by tacrolimus and deletion of recombination activating gene 1.

European cells & materials·2021
Same journal

Facial Dysmorphism and Severe Vascular Phenotype in TRNT1 Deficiency with Concomitant Antithrombin III Deficiency.

Journal of clinical immunology·2026
Same journal

Intersection Between Systemic Autoimmune Diseases, Primary Immunodeficiency and Cancer: a Field in its Infancy.

Journal of clinical immunology·2026
Same journal

Disseminated Tuberculosis and Early-Onset SLE in a Child with a Novel STAT1 Gain-of-Function Mutation: a Case Report.

Journal of clinical immunology·2026
Same journal

Humoral Immune Abnormalities in Transient Childhood Neutropenia: Insights From a 10-year Cohort Study in a Tertiary Center.

Journal of clinical immunology·2026
Same journal

Correction to: Whole Genome Sequencing in 25 Families with Suspected Inborn Errors of Immunity: Diagnostic Yield and Clinical Relevance of Genome-wide Analysis.

Journal of clinical immunology·2026
Same journal

Hypoproteinemia and Hypogammaglobulinemia Due to a Homozygous FCGRT Mutation.

Journal of clinical immunology·2026
See all related articles

Gene therapy offers a promising approach to treating autoimmune disorders by delivering therapeutic genes. This innovative treatment has shown success in animal models and early human trials for rheumatoid arthritis.

Area of Science:

  • Immunology
  • Genetics
  • Biotechnology

Background:

  • Autoimmune disorders, while often lacking a strong genetic basis, present opportunities for improved treatment through gene therapy.
  • Current gene therapy strategies focus on transferring genes that encode immunomodulatory products to beneficially alter host immune responses.
  • Genes act as biological delivery vehicles, overcoming limitations in targeted protein and RNA delivery, enhancing efficacy, duration, and safety.

Purpose of the Study:

  • To explore the potential of gene therapy as a novel treatment modality for autoimmune diseases.
  • To review existing evidence from animal studies and early clinical trials demonstrating the efficacy of gene therapy in autoimmune conditions.
  • To highlight the advantages of gene therapy, including improved delivery, efficacy, and safety profiles for immunomodulatory treatments.

Related Experiment Videos

Main Methods:

  • Gene transfer of immunomodulatory products to alter host immune responses.
  • DNA vaccination strategies.
  • Targeted ablation of specific tissues and cell populations.
  • Pre-clinical studies in animal models of rheumatoid arthritis, multiple sclerosis, diabetes, and lupus.
  • Phase I clinical trial involving the transfer of interleukin-1 receptor antagonist cDNA to treat rheumatoid arthritis.

Main Results:

  • Animal studies demonstrate successful treatment of experimental autoimmune models, including rheumatoid arthritis, multiple sclerosis, diabetes, and lupus.
  • A Phase I clinical trial showed promising results for gene therapy in patients with advanced rheumatoid arthritis.
  • Two additional clinical trials are currently underway, indicating progress in the clinical application of gene therapy for autoimmune diseases.

Conclusions:

  • Gene therapy presents a viable and effective strategy for treating a variety of autoimmune disorders.
  • The use of genes as delivery vehicles enhances the targeted delivery and efficacy of immunomodulatory agents.
  • Successful pre-clinical and early clinical data suggest a significant future role for gene therapy in managing autoimmune diseases.